Literature DB >> 9727874

Time-dependent changes in CT-based dosimetry of I-125 prostate brachytherapy.

J Willins1, K Wallner.   

Abstract

To determine the effect of time between prostate brachytherapy and evaluation CT scan on calculated target coverage. CT scans from 11 consecutive, unselected patients with stage T1 or T2 prostatic carcinoma who had transperineal I-125 implants at MSKCC in 1996 were analyzed for target coverage at 0, 2, and 6 months after implantation. The outer margins of the prostate were outlined on each CT section by a single investigator. In each CT plane, the prescription isodose (150 Gy) was overlaid on the target contour from the postimplant CT to calculate the integral Dose-Volume Histogram. The postimplant target volume on the day of the implant ranged from 93% to 160% of the preimplant volume (average: 117%). In all patients, the target size returned to the preimplant size or smaller within 2 months of the procedure and was relatively stable between 2 to 6 months. Immediately following the implant, an average of 84% of the target (range: 73-98%) was covered by the 150 Gy isodose line. Consistent with changes in the target volume over time, the target coverage increased from an average of 84% to 90% between 0 to 2 months and did not change substantially between 2 and 6 months. There was minimal source loss from the target area after the implant. It was concluded that temporary, postimplant swelling will increase the target volume, making target coverage inferior to what would be calculated if a dosimetry scan was taken sometime later, after the acute swelling has subsided. Until the clinical significance of the effect of postimplant volume changes is better defined, we are continuing to obtain evaluation scans on the day of the implant.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9727874     DOI: 10.1002/(SICI)1520-6823(1998)6:4<157::AID-ROI2>3.0.CO;2-X

Source DB:  PubMed          Journal:  Radiat Oncol Investig        ISSN: 1065-7541


  3 in total

1.  On the need to compensate for edema-induced dose reductions in preplanned (131)Cs prostate brachytherapy.

Authors:  Z Jay Chen; Jun Deng; Kenneth Roberts; Ravinder Nath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

2.  Correlations of post-implant regional dosimetric parameters at 24 hours and one month, with clinical results of low-dose-rate brachytherapy for localized prostate cancer.

Authors:  Eiichiro Okazaki; Katsuyuki Kuratsukuri; Kentaro Ishii; Tomoaki Tanaka; Ryo Ogino; Tomohiro Nishikawa; Hideyuki Morimoto; Masako Hosono; Yukio Miki
Journal:  J Contemp Brachytherapy       Date:  2017-12-30

3.  Comparison of two treatment approaches for prostate cancer: intensity-modulated radiation therapy combined with 125I seed-implant brachytherapy or 125I seed-implant brachytherapy alone.

Authors:  Yulin Song; Maria F Chan; Chandra Burman; Donald Cann
Journal:  J Appl Clin Med Phys       Date:  2008-03-18       Impact factor: 2.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.